Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 7/20 | 0.38 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907376 | 0.84 | CYP1A2 (0.40) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14907424 | 0.77 | LMNA (0.49) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14907420 | 0.74 | KMT2A (0.45) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14907393 | 0.74 | CYP3A4 (0.45) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14907400 | 0.73 | HPGD (0.53) | MAPTPTGESALDH1A1ALOX5CYP2C9 | |
| SCHEMBL14907392 | 0.70 | FABP4 (0.40) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14907414 | 0.69 | MAPT (0.59) | MAPK1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16097168 | 0.69 | MCL1 (0.46) | MAPTKMT2ANPSR1PTGESALDH1A1 | |
| SCHEMBL16097708 | 0.68 | ESR1 (0.46) | PTGESALDH1A1ALOX5CYP2C9HPGD | |
| SCHEMBL16098232 | 0.66 | MAPK1 (0.54) | MAPK1MEN1KMT2APTGESALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819662-B1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| WO-2013127011-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013059944-A1 | EPIGENETIC REGULATORS AND USES THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | CBX2, BPTF, CBX4 | MAPK1 3817/4885MAPT 2511/4885CYP1A2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.